A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). This is an ASCO Meeting Abstract from ...
PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial ...
Solid Biosciences has reported promising initial findings from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first three ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The allogenic cell therapy achieved all primary and ...
Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on its candidate for metastatic or refractory cancers, INT230-6. The asset ...
CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results